



(51) International Patent Classification:

G01N 33/543 (2006.01) G01N 33/566 (2006.01)
G01N 33/53 (2006.01) G01N 33/569 (2006.01)

(21) International Application Number:

PCT/US2021/026377

(22) International Filing Date:

08 April 2021 (08.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/008,786 12 April 2020 (12.04.2020) US

(71) Applicant: **AETHLON MEDICAL, INC.** [US/US];
11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 (US).

(72) Inventors: **FISHER, JR., Charles J.**; 2164 Cambridge Avenue, Cardiff-by-the-Sea, California 92007 (US). **CAMPION, Rosalia De Necochea**; 2301 Mesa Drive, Ocean-side, California 92054 (US). **LAROSA, Steven P.**; 23 Junction Lane, South Hamilton, Massachusetts 01982 (US). **MARLEAU, Annette**; c/o Aethlon Medical, Inc., 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 (US). **JACOBS, Michael**; c/o Aethlon Medical, Inc., 11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 (US).

(74) Agent: **FURMAN, Eric S.**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: DEVICES AND METHODS FOR TREATING A CORONAVIRUS INFECTION AND SYMPTOMS THEREOF




FIG. 13B

(57) **Abstract:** The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post- COVID- 19 syndrome or similar post-disease sequelae so-called "long haul" symptoms of COVID-19 or similar disease. The present invention benefits patients by providing lectin based extracorporeal methods for binding and physically removing SA RS-C7oV-2 virions, or fragments thereof, from the circulatory system. Also provided are lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity/mortality of diseases such as COVID-19 and similar diseases, including cytokines, such as IL- 6, Troponin T, and D- dimer.

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*